质量水平
检测方案
≥98% (HPLC)
形式
solid
溶解性
H2O: >5 mg/mL
创始人
Novartis
SMILES字符串
Cl[H].CCOC(=O)[C@H](CCc1ccccc1)N[C@H]2CCc3ccccc3N(CC(O)=O)C2=O
InChI
1S/C24H28N2O5.ClH/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28;/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28);1H/t19-,20-;/m0./s1
InChI key
VPSRQEHTHIMDQM-FKLPMGAJSA-N
基因信息
human ... ACE(1636)
正在寻找类似产品? 访问 产品对比指南
生化/生理作用
贝那普利是一种长效的血管紧张素转换酶 (ACE) 抑制剂。
特点和优势
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语：
Warning
危险声明
危险分类
Repr. 2
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
Yoshihiko Kanno et al.
Hypertension research : official journal of the Japanese Society of Hypertension, 25(6), 939-943 (2002-12-18)
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disorder in humans. Hypertension is one of the major complications, and its control might affect the renal survival and disease mortality. Suitable antihypertensive agents have been discussed based
Daphne P Bicket
American family physician, 66(3), 461-468 (2002-08-17)
When first introduced in 1981, angiotensin-converting enzyme (ACE) inhibitors were indicated only for treatment of refractory hypertension. Since then, they have been shown to reduce morbidity or mortality in congestive heart failure, myocardial infarction, diabetes mellitus, chronic renal insufficiency, and
A Salvetti et al.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 12(8), S91-S94 (1994-11-01)
SHORT- VERSUS LONG-ACTING ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS: Although ACE inhibitors are widely used in the treatment of hypertension, there are few data on trough:peak ratios and the data are contradictory. Part of the explanation for this lies in differences
Nadine Bongaerts et al.
Nature communications, 13(1), 3905-3905 (2022-07-08)
Whole-cell screening for Mycobacterium tuberculosis (Mtb) inhibitors is complicated by the pathogen's slow growth and biocontainment requirements. Here we present a synthetic biology framework for assaying Mtb drug targets in engineered E. coli. We construct Target Essential Surrogate E. coli
Bjoern B Burckhardt et al.
Journal of pharmaceutical and biomedical analysis, 96, 118-126 (2014-04-18)
Although serum and plasma are the biological fluids of choice for pharmacokinetic determination of drugs in adults, it is desirable to elucidate noninvasive methods which can be used for investigations in vulnerable groups such as children. If the drug properties
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门